Next-Generation
Immunotherapeutics
Precision
Immunomodulation
Diseases
Active Immunomodulation IS ONE OF THE MOST
promising approaches in modern precision medicine.
To bring this to the next level, we at ingineeon develop
first-in-class cytokine-based immunotherapeutics.
Our therapeutics have breakthrough potential in infectious diseases,
immuno-oncology and autoimmunity.
Ingineeon is a Munich-based biotech company. Its pipeline is built on
world-leading research at the Technical University of Munich.
Our therapeutics are based on advanced molecular engineering
and have been validated in fully human ex vivo patient studies.
In a defined path forward, we at ingineeon will soon bring our
first-in-class immunotherapeutics to the clinics for the
benefit of patients in need.
Science
Our Approach
We at ingineeon are driven by science to make
precise and effective therapies a reality.
Cytokines are master regulators of our immune system. At ingineeon we focus on immunomodulatory cytokines that precisely target key disease drivers. We have world-leading know-how to develop cytokines with desired functions to enhance, restore or rebalance immune functions with unprecedented precision.
Our science-driven approach provides us with an unique, innovative set of engineered cytokine-based therapeutics. Each of our assets builds on and precisely leverages the natural functions of our immune system.
Our therapeutics overcome current limitations in the field of cytokine-based drugs. At the same time our approach maximizes the chances for therapeutic success in our developments from the very beginning on.
Complementing our pipeline of first-in-class immunotherapeutics, ingineeon has developed platform technologies for advanced cell therapies and protein production.
Science
Our Therapeutics
Breakthrough science is the key ingredient in our next‑generation biologics
IL‑27alpha‑based biologic
Impaired immunity is a major disease driver in systemic inflammations like sepsis but also cancer, e.g. checkpoint inhibitor therapies.
We have developed the worldwide first human interleukin‑27alpha‑based immunotherapeutic (INGp‑010X). INGp‑010X is a first-in-class biopharmaceutical with a novel Mechanism of Action for precise restoration of immune competence.
Building on in vivo animal and ex vivo human Proof of Concepts, INGp‑010X is only few milestones away from entry into the clinics.
IL‑35‑based biologic
Autoimmunity is an increasing health problem with currently only limited therapeutic options.
Millions of patients have to live with a significantly reduced Quality of Life.
We have developed INGp‑011X, an interleukin‑35‑based biologic. As demonstrated by our ex vivo human studies, INGp‑011X is a first-in-class immunotherapeutic that enables our immune system to precisely gain tolerance for stimuli of autoimmunity. Thus, INGp‑011X directly addresses causal key disease drivers.
Science
Our Technologies
Our expertise enables us to develop platform biotechnologies
that overcome major hurdles in the field:
i-TAG PLATFORM
i-Tag: an enabling platform biotechnology for standardized and efficient protein production.
Most proteins do not share common structural features. Many of these proteins have a tremendous therapeutic potential, but are often hard to produce and not amenable to established developability platforms.
To address this bottleneck, we have developed the i-Tag as an enabling platform biotechnology for a standardized, efficient production and developability of proteins.
Advanced cell therapies
Solid tumors remain hard-to-treat with cell therapies like CAR T-cells.
We have developed a self-deactivating version of interleukin 12 that potentiates the action of cell therapies in immunosuppressive microenvironments.
At the same time, side-effects are avoided that come along with systemically boosting immune responses.
Interested to learn more and to discuss
in-licensing options of our platform technologies?
Pipeline
Immunotherapeutics
We develop first-in-class precision immunotherapeutics for major unmet medical needs. With a robust proof of concept and preclinical validation, a defined route to clinic and market, we are ready to bring our assets to patients eagerly awaiting novel treatment options.
Cytokine-based, first-in-class immunotherapeutics | compound class: biologics
Cytokine-based, first-in-class immunotherapeutics | compound class: biologics
| Compound | Indication(s) (Program) |
Discovery pre‑clinical |
Preclinical POC |
Final IND‑enabling |
Phase 1 |
Clinical Phase 2 |
Phase 3 |
Worldwide rights |
|---|---|---|---|---|---|---|---|---|
 |
INFECTIOUS DISEASES: SEPSIS (INGp‑0101) |
* |  |
|||||
| IMMUNO ONCOLOGY (INGp‑0104) |
|
|||||||
 |
AUTOIMMUNITY 1 (INGp‑0111) |
|
||||||
| AUTOIMMUNITY 2 (INGp‑0112) |
|
|||||||
| AUTOIMMUNITY 3 (INGp‑0113) |
|
|||||||
*
Positive opinion from regulatory
authority on therapeutic breakthrough
potential and accelerated market access
Team
Our
Synergistic expertise
from Science, Clinics & Industry
Committed KOLs
& Clinical Centers
HQs in Munich
We combine >100 years of expertise from science, the clinics and the industry within our co‑founder team to develop next‑generation immunotherapeutics and to make untreatable diseases treatable.
This expertise is leveraged by the whole ingineeon team and the support of world‑leading scientists, clinicians, entrepreneurs and industry experts.
With our headquarters embedded in the thriving biotech scene South of Munich in Germany, ingineeon is perfectly set to bring its breakthrough innovations to the clinics.
Management
Our
Julia Behnke
Chief Executive Officer, Dr. EMBA
"I love smart people, cool science, and making an impact.
Developing next-generation immunotherapeutics as well as useful biotechnologies and ultimately helping patients is exactly that to me. This is my why building ingineeon.
All of this is also now at the very heart of everything we do at ingineeon. With a strong team, innovative, validated technologies with breakthrough potential as a foundation, I am very much looking forward to the next steps ahead of us."
Matthias Feige
Chief Scientific Officer, Prof. Dr.
"Science drives me, making an impact, motivates me.
I have dedicated my entire career to an understanding of how our cells make the molecules that allow them to communicate with each other and to defend against threats. This has always happened at the boundaries between basic science and pharma as well as biotech developments, to see our ideas make an impact.
Now at ingineeon I contribute this to develop next generation immune drugs that can really make a change."
Dorothee Ambrosius
Chief Development (CMC)
and Technology Officer, Dr.
"My passion and enthusiasm is to translate new research findings into innovative biological medicines for the benefit of our patients.
ingineeon has discovered highly innovative novel medical treatment approaches based on immunotherapeutics, and I am proud to be part of this team to drive the implementation of these innovatons into a product.
I am excited to work in a strong and diverse team, together with external partners, to solve problems and remove roadblocks."
Melanie Laschinger
Efficacy and Safety Studies Director, PD Dr.
"Helping patients in need through advanced immunotherapeutics.
This mission is deeply personal to me as it allows me to drive innovation in an scientific field that I am not only truly passionate about but have also dedicated my entire career to.
I love working with our diverse team of incredibly talented and scientifically brilliant people who share this vision. Building ingineeon is not just a career move - it's an opportunity to make a real impact on the lives of those patients who need it most. And to me, that's what makes this journey so exciting."
Bernhard Holzmann
Director Immunology, Prof. Dr.
"Our immune system protects us against pathogens like bacteria and viruses, but, when out of balance, may become a key driver of disorders like sepsis, autoimmunity, and allergies.
My scientific work focuses on deciphering disease-driving processes of immune responses, with the aim to use this knowledge for identifying novel therapeutic approaches.
I am enthusiastic about being part of the ingineeon team translating scientific achievements into first-in-class immunotherapeutics to render some of the most common untreatable diseases treatable."
Isabel Aschenbrenner
Program and Operations Lead, Dr.
"I truly enjoy being part of a company from the very first steps towards an organization delivering meaningful immunotherapeutics for patients urgently awaiting new treatment options.
It is inspiring to see how the scientific understanding of cytokine biology I developed throughout my academic career now enriches and strengthens ingineeon's translational work.
I'm driven by the ambition to shape an organization that creates real impact while fostering a team culture in which we grow to our full potential together."
News&Media
PRESS RELEASE
BIORIVER
„Recognized as the nr.1 biotech start-up that will shape our future. By leaders from industry and finance."
MEET INGINEEON LIVE
HC8
HALLE CONFERENCE ON RECOMBINANT PROTEINS,
HALLE, GER
MARCH 12-13, 2026
Latest findings on the development, application, manufacturing and characterization of modern protein drugs presented by academia and industry
Don´t miss our presentation
MEET INGINEEON LIVE
DBT
GERMAN BIOTECH DAYS,
LEIPZIG, GER
APRIL 21-22, 2026
The German Biotech Days bring together entrepreneurs with scientists and partners from politics, investors, funding institutions and administration. The event is the national forum for the German and international biotechnology industry.
Don´t miss our presentation
MEET INGINEEON LIVE
FOB
FESTIVAL OF BIOLOGICS,
BASEL, CHE
OCTOBER 13-15, 2026
The Festival of Biologics Basel is Europe’s largest biologics event. Designed for industry experts in pharma and biotech, start-ups, academics, regulators and investors, the Festival of Biologics is the meeting place for the large molecule therapy ecosystem,
Don´t miss our presentation